CA-VIZ.AI
4.3.2023 14:01:45 CET | Business Wire | Press release
Viz.ai, the leader in AI-powered disease detection and care coordination, today announced it will use its VizTM RECRUIT platform to optimize patient enrollment for the NIH-funded1 Pulmonary Embolism—Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial. The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.
The PE-TRACT trial is designed to address whether catheter therapy should be routinely used to treat intermediate-risk pulmonary embolism versus anticoagulants alone. Pulmonary embolism occurs when a blood clot is trapped in an artery in the lung, blocking blood flow to part of the lung.
“The PE-TRACT trial will offer a deeper knowledge of pulmonary embolism by providing a comprehensive comparison of catheter-directed therapy plus anticoagulation to anticoagulation alone,” said Dr. Akhilesh Sista, [Principal Investigator of the PE-TRACT trial, Interventional Radiologist and Faculty, Weill Cornell Medical College]. “PE-TRACT will provide valuable insights to patients and providers regarding which approach best maintains cardiopulmonary health in the year following PE. Viz.ai’s RECRUIT tool has the potential to efficiently identify potential participants and help this important trial complete enrollment on time.”
Participating research institutions in the PE-TRACT trial will use Viz RECRUIT to find, screen, and enroll clinical trial candidates. Viz RECRUIT, an AI-powered clinical trial enrollment platform, automates the identification and triage of eligible candidates for pre-trial review, while reducing the burden on the research team. Using Viz RECRUIT, sites will be able to automatically screen patients based on pulmonary embolism and high right ventricular to left ventricular diameter (RV/LV) ratio. The cloud-based technology helps to broaden the recruitment funnel in both size and diversity and streamlines the trial enrollment workflow. To date, Viz RECRUIT has been used to screen nearly 300,000 patients and identify over 14,000 clinical trial candidates across 100 healthcare facilities.
“We’re honored to be the partner of choice for this clinical trial to accelerate vascular research using Viz RECRUIT. With our platform’s real-world accuracy and demonstrated success, researchers can use AI to identify potentially eligible trial candidates, regardless of their location, ultimately expediting the clinical trial enrollment process,” said Jayme Strauss, chief clinical officer, Viz.ai. “We aim to expand the participation and diversity of participants in clinical research to make treatments safer for all patients and advance the development of novel treatments, while empowering research teams to efficiently and consistently screen for patients and coordinate research.”
Information on the PE-TRACT trial and the Viz RECRUIT platform will be presented at the upcoming Society of Interventional Radiology Meeting on March 7 in Phoenix, Arizona. To learn more, please visit the Viz.ai website.
1 The study was funded by the National Heart, Lung, and Blood Institute, of the National Institutes of Health, under grant award number 1UG3HL155798-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase access to life-saving treatments, covering more than 200 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230304005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Welcomes Wave of New Licensees to the HEVC Advance Patent Pool8.7.2026 02:00:00 CEST | Press release
Access Advance LLC, the leading HEVC patent pool administrator, today announced a significant expansion of the HEVC Advance Patent Pool, with 28 companies executing licenses in the first half of 2026. The new Licensees span consumer electronics, automotive, telecommunications, industrial technology, and professional security, reflecting the breadth of industries in which HEVC has become a foundational video technology. "HEVC remains the cornerstone of modern video delivery, and the demand we are seeing from new Licensees speaks to the long-term commercial relevance of this technology," said Peter Moller, CEO of Access Advance. "HEVC licensing activity has been consistently strong, and we are pleased to welcome a number of important new participants to the program." Notably, nine video surveillance equipment manufacturers have joined the HEVC Advance program as Licensees, ranging from three of the world's largest video surveillance equipment makers to specialized developers of security
Empire State Building Observation Deck Run-Up Returns for 48th Annual Race on Oct. 68.7.2026 00:22:00 CEST | Press release
Presented by NYU Langone Health and Powered by MerrellLottery Open Through July 20 The Empire State Building Observation Deck (ESB), atop the “World’s Most Famous Building,” today announced that general lottery registration is open for this year's Empire State Building Observation Deck Run-Up (ESBRU), which will run through July 20, 2026. The annual race, presented by NYU Langone Health and powered by Merrell, will take place on Oct. 6, 2026, at 8 p.m. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707902561/en/ Empire State Building Observation Deck Run-Up Returns for 48th Annual Race on Oct. 6 This year’s race marks the 48th anniversary of the event, in which 225 runners will race up 1,576 stairs of the iconic New York City landmark to reach the world-famous 86th Floor Observation Deck. “Every year, the Empire State Building Observation Deck Run-Up is a remarkable feat for all who participate as they race up to Tripadvi
Modon's Hudayriyat Golf Estates Sets UAE Record With More Than AED 13 Billion in Sales Within Days of Launch7.7.2026 20:36:00 CEST | Press release
A record-breaking sales value for a residential project in the UAEThe project comprises golf mansions, villas, and townhouses across Hudayriyat Island, Abu Dhabi1,700 residences sold within days after the launch15% non-UAE resident buyers81% new customers to Modon Modon has set a new benchmark for the UAE real estate market with the launch of Hudayriyat Golf Estates on Hudayriyat Island, Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707126559/en/ Modon's Hudayriyat Golf Estates sets UAE record with more than AED 13 billion in sales within days of launch (Photo: AETOSWire) Within days of launch, the community achieved record-breaking sales exceeding AED 13 billion, marking the highest publicly recorded sales value for a single residential project launch in the UAE. Comprising an exclusive collection of golf mansions, villas, and townhouses, the development saw 1,700 of its residences sold after few days of laun
Loomis Sayles Growth Equity Strategies Team Celebrates Twenty-Year Milestones7.7.2026 16:36:00 CEST | Press release
Loomis, Sayles & Company, the century-old investment manager with nearly $418 billion in assets under management, proudly celebrates the 20-year anniversaries of the Loomis Sayles Large Cap Growth and the Loomis Sayles All Cap Growth strategies, as well as a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707992418/en/ Celebrating 20 Years of The Power of Active Management Done Right GES is a cohesive team with 20 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to $98.2 billion
Integral Ad Science Appoints Lidiane Jones Chief Executive Officer7.7.2026 15:35:00 CEST | Press release
Accomplished AI and technology executive to lead IAS's next phase of innovation and growth; Lisa Utzschneider to serve as Special Advisor to the Board through year-end Integral Ad Science (IAS), one of the world's most trusted media quality companies, today announced the appointment of Lidiane Jones as Chief Executive Officer, effective immediately. Jones succeeds Lisa Utzschneider, who led IAS for more than seven years and will remain with the company as Special Advisor to the Board through the end of 2026 to support a seamless transition. Utzschneider will also serve as a Special Advisor to Novacap and their portfolio companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707780892/en/ Lidiane Jones: Integral Ad Science CEO, Photo Credit: Pamela Hanson The appointment reflects IAS's long-term strategic vision for the future of digital advertising. As AI transforms how media is planned, bought, measured, and optimized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom